Blackstone Leads $1.3bn Private Financing for Paratek-Radius Merger
Blackstone Inc is spearheading a $1.3bn private funding package to support the merger of Paratek Pharmaceuticals and Radius Health, with Blackstone Credit & Insurance structuring the financing and acting as one of the largest lenders, according to Private Equity Wire. Sixth Street Partners contributed over $400m to the deal, while additional participants include Oaktree Capital Management and Silver Point Capital. This transaction follows Blackstone’s earlier involvement in a $100m private credit facility for genomic testing firm GeneDx earlier this month.
Details of the Financing
Blackstone Credit & Insurance structured the $1.3bn package, positioning itself as a major lender alongside Sixth Street Partners’ contribution of over $400m. The funding aims to facilitate the merger, and the combined entity is expected to generate approximately $1bn in revenue in 2026. Jonathan Brayman, managing director at Blackstone Credit & Insurance, stated that the deal highlights the firm’s capacity to deliver large-scale capital solutions to life sciences companies.
Participants and Trends
In addition to Blackstone and Sixth Street Partners, Oaktree Capital Management and Silver Point Capital participated in the financing. The transaction reflects a broader trend of private credit funds seeking lending opportunities outside the software sector, where AI-driven disruption is occurring, as noted in the report by Private Equity Wire.
Blackstone’s Recent Activities
Earlier this month, Blackstone led a $100m private credit facility for GeneDx, a genomic testing firm, demonstrating the firm’s ongoing engagement in similar deals. This follows their role in the Paratek-Radius merger financing, underscoring their active presence in private credit for life sciences, according to the source.
